Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

ImmunityBio (IBRX) Other Gross PP&E Adjustments (2016 - 2026)

ImmunityBio has reported Other Gross PP&E Adjustments over the past 12 years, most recently at $177.0 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 3.04% to $177.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $177.0 million through Dec 2025, down 3.04% year-over-year, with the annual reading at $177.0 million for FY2025, 3.04% down from the prior year.
  • Other Gross PP&E Adjustments was $177.0 million for Q4 2025 at ImmunityBio, down from $205.1 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $205.1 million in Q3 2025 and troughed at $76.5 million in Q4 2021.
  • The 5-year median for Other Gross PP&E Adjustments is $179.4 million (2023), against an average of $161.7 million.
  • Year-over-year, Other Gross PP&E Adjustments dropped 7.77% in 2021 and then skyrocketed 91.06% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $76.5 million in 2021, then surged by 91.06% to $146.2 million in 2022, then increased by 17.21% to $171.4 million in 2023, then increased by 6.51% to $182.5 million in 2024, then decreased by 3.04% to $177.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Gross PP&E Adjustments are $177.0 million (Q4 2025), $205.1 million (Q3 2025), and $203.1 million (Q2 2025).